2016-03-11T00:00:00.000-05:00
pancreatic cancer,-0.530878
collaboration,0.280559
unique oncology platform,0.506943
Phil Serlin,0.229502
preclinical data,-0.0572698
treatment,-0.202593
food supplement,0.597945
bone marrow failure,-0.357806
study,0.0296515
leukemic progenitor cells,-0.227277
bone marrow,-0.426589
unmet medical need,-0.424349
minimal residual disease,-0.367578
stem cell,-0.395204
blind placebo-controlled study,-0.764944
small clinical trial,0.572501
Kinneret Savitsky,-0.402978
AML clinical study,-0.278625
refractory AML,-0.305026
immune checkpoint inhibitors,-0.537718
FLT3-ITD-mutated AML patients,0.334289
BL-8040,-0.0211153
clinical response rate,-0.269564
AML progenitor cells,-0.535219
metastatic pancreatic cancer,-0.34434
treatment cycle,0.286527
AML patients,-0.151755
Operator Instructions,0.266285
clinical development strategy,0.376689
aggressive clinical development,0.376689
novel clinical stage,0.602513
tumor micro environment,-0.503675
peripheral blood,-0.463894
immune checkpoint,-0.537718
consolidation therapy,-0.288401
BL-8040 CXCR4 antagonist,-0.34434
Omega Pharma,0.33226
AML cancer cells,-0.461258
forward-looking statements,-0.325351
celiac disease,-0.471457
